Anavex Life Sciences Corp (AVXL)

[polarbear77]

Completely agree with that assessment jvmho, the Company’s been in stealth mode for at least 2 years, and I’ll trust that Dr M and the BOD have their (competitive) reasons.

And you’re right, there’ve still been multiple signs and signals of confidence in the moa and efficacy to date: expanding the pdd trial to AU; expanding the RS Avatar trial to AU in May; letting us know in a conf call that the Spain pdd participants had requested an extension; purchasing 1 million worth of 2-73 inventory; putting in place a large 250 million shelf (commercialization needs?); new patents such as https://patentscope.wipo.int/search/en/detail.jsf?docId=US236451262&tab=NATIONALBIBLIO&office=&prevFilter=%26fq%3DICF_M%3A%22A61K%22&sortOption=Pub+Date+Desc&queryString=&recNum=213&maxRec=2035248

And,

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220180360796%22.PGNR.&OS=DN/20180360796&RS=DN/20180360796

Also telling were the hiring of Dr Walter Kauffman as our CMO this year, and the display of confidence by Dr Missling when explaining Anavex’s moa/efficacy during the March 2019 ROTH conference panel “Alzheimer’s: Beyond the Rise and Fall of Amyloid”.

Stark contrast between our “rapidly advancing” pipeline compared with the BP giants dropping out of the CNS space and “Biogen on the Brink” (credit Jon Jones & nidan) https://www.bizjournals.com/boston/news/2019/08/02/biogen-on-the-brink-one-of-the-states-largest.html?ana=yahoo&yptr=yahoo

The market forces (BP giants and their entrenched tau/amyloid plaque scientists/media/Hedge funds/FUD agents) are by now aware of Anavex and our consortium/Hampel ties and PM leadership & our expanding/extending CNS trials, and I’m convinced that their game plan has been/is to keep Anavex marginalized for as long as possible.

With compounds that are purported to prompt the body to heal itself and self-correct (as well as modulate autophagy) & thereby potentially treat a WIDE range of various CNS afflictions and diseases (reference our pipeline)
https://www.anavex.com/#!/aboutus
it’s not difficult to understand why our small Company would be quite disruptive and thereby threaten the industry leaders & their treatment centers/billions/side-effect-riddled SOC.

https://www.globenewswire.com/news-release/2019/03/04/1745838/0/en/Anavex-Life-Sciences-Reports-Publication-of-New-Data-that-Show-ANAVEX-2-73-Induces-Cellular-Recycling-Process-Linked-to-the-Prevention-and-Treatment-of-Age-Associated-Diseases.html

Godspeed to the researchers and patients and EU/EMA/AU regulators in our trials.

Will be interesting to see if the BP-beholden Congress/FDA will display leadership & respond quickly and favorably (given our excellent safety record and positive RWE reported by our ph2a patients) if our PDD/Rett trials meet or exceed primary endpoints in the coming 3-4 months.

CNS disease-afflicted patients deserve better treatment options and fewer serious side-effects than the current SOC.

GLTAL



[https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/congress-big-pharma-money-123757664.html
“I’m really much more concerned because Congress is supposed to have oversight for the FDA,” Brown said. “If the FDA isn’t going to hold pharma accountable, and Congress is getting paid to not hold pharma accountable, then it really doesn’t matter who the president is because it’s really about Congress.”]